Investment trends and outlook in 2017
Our Investor Perception Survey 2017 highlighted key trends around M&A, Inve...
Read MoreThe headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.
Remember:
Get our executive insight into your inbox
Written By
Lea Bidiville
5 April 2017
Our Investor Perception Survey 2017 highlighted key trends around M&A, Inve...
Read MoreOur Investor Portal is a unique, powerful and searchable resource and libra...
Read MoreBiotech and Money is proud to announce the launch of our inaugural Healthca...
Read MoreWho are some of the leading international investors most active this side o...
Read MoreBiotech and Money are pleased to announce the release of the latest Drugs &...
Read MoreFrancesco de Rubertis, Co-Founder and Partner of Medicxi Ventures, talks to...
Read MoreAnker Lundemose, CEO of MISSION Therapeutics talks to Biotech and Money abo...
Read MoreBiotech and Money had the opportunity to speak to Andy Smith CIO of Mann Bi...
Read MoreWe recently spoke to Andy Richards, Serial Biotechnology Entrepreneur and B...
Read MoreWe recently spoke to Paul Claydon, Partner, Covington at Biotech and Money ...
Read MoreWe recently spoke toPeter George, CEO, Clinigen at Biotech and Money London...
Read More3 months into his tenure as CEO of NetScientific, the vastly experienced in...
Read MoreThe Drugs & Dealers Blog provides genuine thought leadership, exclusive executive insight and market intelligence on the life science and healthcare investment sector.
In partnership with Medius Associates
Medius' monthly review of the top deals by value in the healthcare sector
Connecting Europe's Life Science corporates with capital.
Biotech and Money is the influential community of senior life science decision makers
© 2016 All Rights Reserved By Biotech and Money
Add Your Response